A recent study reveals that individuals who discontinue popular weight-loss injections like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who stop traditional lifestyle programs.
Research printed in a major medical journal demonstrates that while obese people often shed about a fifth of their body weight while on the medication, the weight comes back at an average rate of 0.8 kg per month once they quit.
"People purchasing these drugs should be cognizant of the risk of rapid rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
This pace of recovery implies a reversion to starting mass within about 18 months.
Analyzing Approaches
The analysis, which looked at 37 of trials involving thousands of participants, compared the outcomes of these new drugs with other pills.
Scientists emphasize that individuals who lose weight through dieting usually have a slower creep back—perhaps 100 grams monthly—once they finish.
Explaining the Quick Regain
Nutrition scientists propose the mechanism of the jabs is key to understanding the accelerated regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production may cause the body to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement leads to hunger is unsuppressed, making excessive eating much more probable."
An Ongoing Issue?
Health authorities advise the injections for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, due to the significant potential of weight regain, the therapy is often life-long.
This opinion is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent nature of obesity," akin to managing diseases like hypertension.
Patient Testimonies
Users who have discontinued the jabs explain a sudden resurgence of appetite.
"I experienced a switch activating and I was suddenly starving," said one woman.
This challenge is compounded if users have not developed sustainable dietary or behavioural changes during therapy.
Growing Use
Recent estimates suggest that millions of adults in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone fix and lasting health benefits likely depends on ongoing behavioural changes.
